Business Context and Reporting Period
This Form 6-K filing by Novo Nordisk A/S is dated February 11, 2026. The report discloses transactions in Novo Nordisk shares by board members, executives, and associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company is a leading global healthcare firm headquartered in Denmark, focusing on defeating serious chronic diseases, particularly diabetes.
Key Financial Metrics and Transaction Details
The filing does not contain consolidated financial statements, revenue, profit, cash flow, or debt metrics. It exclusively details insider trading activity for the Executive Vice President and Chief Financial Officer, Karsten Munk Knudsen, on February 10, 2026:
- Transaction Type: Sale of shares (Novo Nordisk B, DK0062498333).
- Total Volume: 26,557 shares sold across two venues.
- Total Value: DKK 8,381,420.30.
- Transaction Breakdown:
- 26,246 shares sold at DKK 315.60 via Jane Street Netherlands B.V. (Value: DKK 8,283,237.60).
- 311 shares sold at DKK 315.70 via CBOE Europe - DXE Periodic (NL) (Value: DKK 98,182.70).
Material Changes
The filing text does not provide comparative data against prior periods or disclose material changes to the company's financial position or operations. The document serves solely as a regulatory notification of specific executive share sales.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a standard compliance report regarding insider trading disclosures.
Key Facts for Investor Verification
- Verify the total number of shares held by Karsten Munk Knudsen post-transaction to assess remaining insider ownership.
- Confirm if this sale aligns with a pre-established trading plan (10b5-1) or represents a discretionary decision.
- Check the prevailing market price of Novo Nordisk B shares on February 10, 2026, to compare against the execution prices of DKK 315.60 and DKK 315.70.
- Note that this filing does not reflect the company's Q4 2025 or full-year 2025 financial results.